The human prostate cancer PC-3 PIP, LNCaP, and C4-2 cell lines are the most often used in preclinical evaluations of PSMA-targeting radioligands [15,17,18,24,25,26,27,28,29,30]. This evidence concerns the gene FOLH1 and prostate carcinoma.